Joffe R T, Post R M, Eil C
Neuropharmacology. 1984 Nov;23(11):1301-3. doi: 10.1016/0028-3908(84)90049-2.
Treatment with carbamazepine is associated with decreases in the serum levels of thyroxine, free thyroxine and triiodothyronine without alteration in the thyrotropin. Therefore, the mechanism of action of carbamazepine on the hypothalamo-pituitary thyroid axis may involve interference in the feedback regulation of secretion of thyroid hormone by interacting with the pituitary thyroid hormone receptors. The present authors investigated the ability of carbamazepine to compete with the nuclear uptake of [125I]triiodothyronine in dispersed intact cultured fibroblasts of human skin. Carbamazepine did not inhibit the specific binding of [125I]triiodothyronine into the nuclei of intact fibroblasts, suggesting that it does not interact with thyroid hormone receptors in this system and is unlikely to do so in vivo.
卡马西平治疗与血清甲状腺素、游离甲状腺素和三碘甲状腺原氨酸水平降低有关,而促甲状腺激素无变化。因此,卡马西平对下丘脑 - 垂体 - 甲状腺轴的作用机制可能涉及通过与垂体甲状腺激素受体相互作用干扰甲状腺激素分泌的反馈调节。本作者研究了卡马西平在人皮肤分散完整培养的成纤维细胞中与[125I]三碘甲状腺原氨酸核摄取竞争的能力。卡马西平不抑制[125I]三碘甲状腺原氨酸与完整成纤维细胞核的特异性结合,表明它在该系统中不与甲状腺激素受体相互作用,在体内也不太可能如此。